Advances in neuroprotection research for neurodegenerative diseases

Advances in Experimental Medicine and Biology

Volumn 541, Issue , 2003, Pages 1-19

  Götz, Mario E ^a   Riederer, Peter ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Clinical Neurochemistry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA TOCOPHEROL; AMANTADINE SULFATE; ASCORBIC ACID; CGP 3466 B; DIHYDROLIPOATE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRA 1,3,5(10),8 TETRAENE 3,17ALPHA DIOL; ESTRADIOL; ESTRADIOL DERIVATIVE; FLUOXETINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; J 811; KAINIC ACID; LADOSTIGIL; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N PROPARGYL 3 AMINOINDAN 5 YL ETHYL METHYL CARBAMATE; NITRIC OXIDE SYNTHASE; PERGOLIDE; PRAMIPEXOLE; QUINOLINIC ACID; RASAGILINE; RESERPINE; RETINOL; ROPINIROLE; SELEGILINE; THIOCTIC ACID; TRYPTOPHAN; UBIQUINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CALCIUM CONDUCTANCE; CLINICAL TRIAL; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RETINOL INTOXICATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOPAMINE AGONISTS; ESTRADIOL; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; PARGYLINE; PROPYLAMINES;

EID: 0347654974     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (178)

1. M. Gerlach, P. Riederer, M. B. Youdim, Neuroprotective therapeutic strategies, comparison of experimental and clinical results, Biochem. Pharmacol. 50(1), 1-16 (1995).
2. E. Grünblatt, R. Schlößer, M. Gerlach, and P. Riederer, Preclinical versus clinical neuroprotection, in Parkinson's disease: Advances in Neurology 91, edited by A. Gordin, S. Kaakkola, and H. Teräväinen (Lippincott Williams & Wilkins, Philadelphia, 2003), pp. 309-328.
3. C. E. Clarke, and M. Guttman, Dopamine agonist monotherapy in Parkinson's disease, Lancet 360(9347), 1767-1769 (2002).
4. W. Birkmayer, P. Riederer, L. Ambrozi, and M. H. Youdim, Implications of combined treatment with "Madopar" and L-deprenyl in Parkinson's disease; A long-term study, Lancet 1(8009), 439-443 (1977).
5. J. Knoll, J. Dallo, and, T.T. Yen, Striatal dopamine, sexual activity and lifespan, Longevity of rats treated with (-) deprenyl, Life Sci. 45(6),525-531 (1989).
6. M. C. Carrillo, K. Kitani, S. Kanai, Y. Sato, K. Miyasaka, and G. O. Ivy, (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old mice, Life Sci. 54(14), 975-981 (1994).
7. I. Mizuta, M. Ohta, K. Ohta, M. Nishimura, E. Mizuta, K. Hayashi, and S. Kuno, Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes, Biochem. Biophys. Res. Commun. 279(3), 751-755 (2000).
8. W. Maruyama, and M. Naoi, Neuroprotection by (-)deprenyl and related compounds, Mech. Aging Dev. 111(2-3), 189-200 (1999).
9. Parkinson Study Group, DATATOP: a multicenter controlled clinical trial in early Parkinson's disease, Arch. Neurol. 46(10), 1052-1060 (1989).
10. Parkinson Study Group, Effect of deprenyl on the progression of disabilityy in early Parkinson's disease, N. Engl. J. Med. 321(20), 1364-1371 (1989).
11. Parkinson Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease, N. Engl. J. Med. 328(3), 176-183 (1993).
12. Parkinson Study Group, Mortality in DATATOP: a multicenter trial in early Parkinson's disease, Ann. Neurol. 43(3), 318-325 (1998).
13. J. W. Tetrud, and J. W. Langston, The effect of deprenyl (selegiline) on the natural history of Parkinson's disease, Science 245(4917), 519-522(1989).
14. H. Przuntek, B. Conrad, J. Dichgans, P. H. Kraus, P. Krauseneck, G. Pergande, U. Rinne, K. Schimrigk, J. Schnitker, and H. P. Vogel, SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur. J. Neurol. 6(2), 141-150 (1999).
15. J. Birks, and L. Flicker, Selegiline for Alzheimer's disease (Cochrane Review), Cochrane Database Syst. Rev. 1, CD000442 (2003).
16. M. Gerlach, M. B. Youdim, and P. Riederer, Pharmacology of selegiline, Neurology 47(6 Suppl 3), S137-145 (1996).
17. K. Magyar, and D. Haberle, Neuroprotective and neuronal rescue effects of selegiline: review, Neurobiology (BP) 7(2), 175-190 (1999).
18. P. C. Waldmeier, A. A. Boulton, A. R. Cools, A. C. Kato, and W. G. Tatton, Neurorescuing effects of the GAPDH ligand CGP 3466B, J. Neural Transm. 60(Suppl.), 197-214 (2000).
19. G. Andringa, and A. R. Cools, The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey, J. Neural Transm. 60(Suppl.), 215-225 (2000).
20. E. Kragten, I. Lalande, K. Zimmermann, S. Roggo, P. Schindler, D. Muller, J. van Oostrum, P. Waldmeier, and P. Furst, Glyceraldehyd-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl, J. Biol. Chem. 273(10), 5821-5828 (1998).
21. K. J. Huebscher, J. Lee, G. Rovelli, B. Ludin, A. Matus, D. Stauffer, and P. Furst, Protein isoaspartyl methyltransferase protects from Bax-induced apoptosis, Gene 240(2), 333-341 (1999).
22. M. B. Youdim, A. Gross, and J. P. Finberg, Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B, Br. J. Pharmacol. 132(2), 500-506 (2001).
23. D. Haberle, K. Magyar, and E. Szoko, Determination of the norepinephrine level by high-performance liquid chromatography to assess the protective effect of MAO-B inhibitors against DSP-4 toxicity, J. Chromatogr. Sci. 40(9), 495-499 (2002).
24. W. Maruyama, T. Yamamoto, K. Kitani, M. C. Carrillo, M. B. Youdim and M. Naoi, Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline, Mech. Aging Dev. 116(2-3), 181-191(2000).
25. W. Maruyama, Y. Akao, M. B. Youdim, and M. Naoi, Neurotoxins induce apoptosis in dopamine neurons; protection by N-propargylamine-1-(R)- and (S)-aminoindan, rasagiline and TV1022, J. Neural Transm. 60(Suppl), 171-186(2000).
26. W. Maruyama, Y. Akao, M. C. Carrillo, K. Kitani, M. B. Youdim, and M. Naoi, Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes, Neurotoxicol. Teratol. 24(5), 675-682 (2002).
27. W. Maruyama, T. Takahashi, M. B. Youdim, and M. Naoi, The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells, J. Neural Transm. 109(4), 467-481 (2002).
28. Y. Akao, W. Maruyama, S. Shimizu, H. Yi, Y. Nakagawa, M. Shamoto-Nagai, M. B. Youdim, Y. Tsujimoto, and M. Naoi, Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan, J. Neurochem. 82(4), 913-923 (2002).
29. J. P. Finberg, and M. B. Youdim, Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours, Neuropharmacology 43(7), 1110-1118 (2002).
30. J. M. Rabey, I. Sagi, M. Huberman, E. Melamed, A. Korczyn, N. Giladi, R. Inzelberg, R. Djaldetti, C. Klein, and G. Berecz, The Rasagiline Study Group, Rasagiline mesylate, a new MAO-B inhibitor, for the treatment of Parkinson's disease: a double blind study as adjunctive therapy to levodopa, Clin. Neuropharmacol. 23(6), 324-330 (2000).
31. Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study, Arch. Neurol. 59(12), 1937-1943 (2002).
32. J. Sterling, Y. Herzig, T. Goren, N. Finkelstein, D. Lemer, W. Goldenberg, I. Miskolczi, S. Molnar, F. Rantal, T. Tamas, G. Toth, A. Zagyva, A. Zekany, G. Lavian, A. Gross, R. Friedman, M. Razin, W. Huang, B. Krais, M. Chorev, M. B. Youdim, and M. Weinstock, Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45(24), 5260-5279 (2002).
33. M. Weinstock, N. Kirschbaum-Slager, P. Lazarovici, C. Bejar, M. B. Youdim and S. Shoham, Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drug, in: Neuroprotective Agents, Ann. N. Y. Acad. Sci. U. S. A. vol. 939, edited by W. Slikker Jr., and B. Trembly (N. Y. Acad. Sci., New York, 2001) pp. 148-161.
34. M. B. Youdim, and M. Weinstock, Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3) aminoindan-5-yl)-etnyl methyl carbamate], Cell. Mol. Neurobiol. 21(6), 555-573 (2001).
35. M. B. Youdim, and M. Weinstock, Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline, Mech. Ageing Dev. 123(8), 1081-1086 (2002).
36. M. Yogev-Falach, T. Amit, O. Bar-Am, M. Weinstock, and M. B. Youdim, Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline, FASEB J. 16(12), 1674-1676 (2002).
37. Parkinson Study Group, Pramipexole vs L-DOPA as initial treatment for Parkinson disease: a randomized controlled trial, JAMA 284(15), 1931-1938(2000).
38. A. Lieberman, A. Ranhosky, and D. Korts, Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study, Neurology 49(1), 162-168 (1997).
39. H. Allain, A. Destee, H. Petit, M. Patay, S. Schuck, D. Bentue-Ferrer, and P. Le Cavorzin, Five-year follow-up of early lisuride and L-DOPA combination therapy versus L-DOPA monotherapy in de novo Parkinson's disease, The French Lisuride Study Group, Eur. Neurol. 44(1), 22-30 (2000).
40. P. Barone, D. Bravi, F. Bermejo-Pareja, R. Marconi, J. Kulisevsky, S. Malagu, R. Weiser, and N. Rost, Pergolide monotherapy in the treatment of early PD: a randomized, controlled study, Neurology 53(), 573-579 (1999).
41. B. Bergamasco, L. Frattola, A. Muratorio, F. Piccoli, F. Mailland, and L. Pametti, α-Dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study, Acta Neurol. Scand. 101(6), 372-380 (2000).
42. L. Battistin, P. G. Bardin, F. Ferro-Milone, C. Ravenna, V. Toso, and G. Reboldi, α-Dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study, Acta Neurol. Scand. 99(1), 36-42 (1999).
43. U. K. Rinne, F. Bracco, C. Chouza, E. Dupont, O. Gershanik, J. F. Marti-Masso, J. L. Montastruc, and C. D. Marsden, Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications, Results of a double-blind L-DOPA controlled trial, The PKDS009 Study Group, Drugs 55(Suppl 1), 23-30 (1998).
44. A. Lledo, Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism Relat. Disord. 7(1), 51-58 (2000).
45. J. P. Bennett, and M. F. Piercey, Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease, J Neurol. Sci. 163(1), 25-31 (1999).
46. P. M. Carvey, S. O. McGuire, and Z. D. Ling, Neuroprotective effects of D3 dopamine receptor agonists, Parkinsonism & Related Disorders 7(3), 213-223 (2001).
47. N. Ogawa, K. Tanaka, M. Asanuma, M. Kawai, T. Masumizu, M. Kohno, and A. Mori, Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro, Brain Res. 657(1-2), 207-213 (1994).
48. T. Yoshikawa, Y. Minamiyama, Y. Naito, and M. Kondo, Antioxidant properties of bromocriptine, a dopamine agonist, J. Neurochem. 62(3), 1034-1038 (1994).
49. A. Ubeda, C. Montesino, M. Paya, and M. J. Alcaraz, Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic. Biol. Med. 15(2), 159-167 (1993).
50. E. E. Sam, and N. Verbeke, Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism, J. Neural Transm. Park. Dis. Dement. Sect. 10(2-3), 115-127 (1995).
51. M. Gassen, Y. Glinka, B. Pinchasi, and M. B. Youdim, Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction, Eur. J. Pharmacol. 308(2), 219-225 (1996).
52. M. Iida, I. Miyazaki, K.-I. Tanaka, H. Kabuto, E. Iwata-Ichikawa, and N. Ogawa, Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist, Brain Res. 838(1-2), 51-59 (1999).
53. T. Kihara, S. Shimohama, H. Sawada, K. Honda, T. Nakamizo, R. Kanki, H. Yamashita, and A. Akaike, Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade, J. Neurosci. Res. 70(3), 274-282 (2002).
54. W. D. Le, and J. Jankovic, Are dopamine receptor agonists neuroprotective in Parkinson's disease?, Drugs Aging 18(6), 389-396 (2001).
55. S. Thobois, S. Guillouet, and E. Broussolle, Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease, Neuophysiol. Clin. 31(5), 321-340 (2001).
56. K. Marek, β-CIT/SPECT assessments of progression of Parkinson's disease in subjects participating in the CALM PD study, Neurology 54(Suppl3), A90 (2000).
57. J. S. Rakshi, N. Pavese, T. Uema, K. Ito, P. K. Morrish, D. L. Bailey, and D. J. Brooks, A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an (18)F-DOPA PET study, J. Neural Transm. 109(12), 1433-1443 (2002).
58. M. E. Götz, G. Künig, P. Riederer, and M. B. Youdim, Oxidative stress: Free radical production in neural degeneration, Pharmac. Ther. 63(1), 37-122 (1994).
59. A. D. Mooradian, Antioxidant properties of steroids, J. Steroid Biochem. Mol. Biol. 45(6), 509-511 (1993).
60. B. Ruiz-Larrea, A. Leal, C. Martin, R. Martinez, and M. Lacort, Effects of estrogens on the redox chemistry of iron: A possible mechanism of the antioxidant action of estrogens, Steroids 60(11),780-783 (1995).
61. C. Behl, M. Widmann, T. Trapp, and F. Holsboer, 17β-estradiol protects neurons from oxidative stress-induced cell death in vitro, Biochem. Biophys. Res. Commun. 216(2), 473-482 (1995).
62. C. Behl, T. Skutella, F. Lezoualc'h, A. Post, M. Widmann, C. J. Newton, and F. Holsboer, Neuroprotection against oxidative stress by estrogens: Structure-activity relationship, Mol. Pharm. 51(4), 535-541 (1997).
63. C. P. Miller, I. Jirkovsky, D. A. Hayhurst, and S. J. Adelman, In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein, Steroids 61(5), 305-308 (1996).
64. +-ATPase activity, glucose transport, and glutamate transport induced by amyloid β-peptide and iron, J. Neurosci. Res. 50(4), 522-530 (1997).
65. W. Römer, M. Oettel, P. Droescher, and S. Schwarz, Novel "scavestrogens" and their radical scavenging effects, iron-chelating, and total antioxidative activities: Δ8,9-dehydro derivatives of 17α-estradiol and 17β-estradiol, Steroids 62(3), 304-310 (1997).
66. D. Blum-Degen, M. Haas, S. Pohli, R. Harth, W. Römer, M. Oettel, P. Riederer, M. E. Götz, Scavestrogens protect IMR 32 cells from oxidative stress - induced cell death, Toxicol. Appl. Pharmacol. 152(1), 49-55 (1998).
67. W. Römer, M. Oettel, B. Menzenbach, P. Droescher, S. Schwarz, Novel estrogens and their radical scavenging effects, iron-chelating, and total antioxidative activities: 17α-substituted analogs of Δ9(11)-dehydro- 17β-estradiol, Steroids 62(11), 688-694 (1997).
68. C. Behl, Vitamin E protects neurons against oxidative cell death in vitro more effectively than 17β-estradiol and induces the activity of the transcription factor NF-kappaB, J. Neural Transm. 107(4), 393-407 (2000).
69. G.A. Fritsma, Vitamin E and autoxidation, Am. J. Med. Tech. 49(6) 453-456 (1983).
70. J.A. Lucy, Functional and structural aspects of biological membranes: a suggested role for vitamin E in the control of membrane permeability and stability. Ann. N. Y. Acad. Sci. 203, 4-11 (1972).
71. J. R. Burton, and K. U. Ingold, Autoxidation of biological molecules. The antioxidant activity of vitamin E and related chain-breaking phenolic antioxidants in vitro, J. Am. Chem. Soc. 103, 6472-6477 (1981).
72. C. K. Chow, Vitamin E and oxidative stress, Free Radic. Biol. Med. 11(2), 215-232 (1991).
73. A. Bjorneboe, G.-E. Bjorneboe, and C. A. Drevon, Absorption, transport and distribution of vitamin E, J. Nutr. 120(3), 233-242 (1989).
74. C. A. Drevon, Absorption, transport and metabolism of vitamin E, Free Radic. Res. Commun. 14(4), 229-246 (1991).
75. R. J. Sokol, Vitamin E and neurologic function in man, Free Radic. Biol. Med. 6(2), 189-207 (1989).
76. G. T. Vatassery, C. K. Angerhofer, and C. A. Knox, Effect of age on vitamin E concentrations in various regions of the brain and a few selected peripheral tissues of the rat, and on the uptake of radioactive vitamin E by various regions of the rat brain, J. Neurochem. 43(2), 409-412 (1984).
77. G. T. Vatassery, Selected aspects of the neurochemistry of vitamin E, in: Clinical and nutritional aspects of vitamin E, edited by, O. Hayaishi, and M. Mino, (Elsevier, Amsterdam, 1987), pp. 147-155.
78. M. A. Goss-Sampson, C. J. McEvilly, and D. P. R. Muller, Longitudinal studies of the neurobiology of vitamin E and other antioxidant systems, and neurological function in the vitamin E deficient rat, J. Neurol. Sci. 87(1), 25-35 (1988).
79. E. Southam, P. K. Thomas, R. H. M. King, M. A. Goss-Sampson, and D. P. R. Muller, (1991) Experimental vitamin E deficiency in rats, morphological and functional evidence of abnormal axonal transport secondary to free radical damage, Brain 114(Pt 2), 915-936 (1991).
80. G. T. Vatassery, C. K. Angerhofer, C. A. Knox, and D. S. Deshmukh, Concentrations of vitamin E in various neuroanatomical regions and subcellular fractions, and the uptake of vitamin E by specific areas, of rat brain, Biochim. Biophys. Acta 792(2), 118-122 (1984).
81. D.A. Butterfield, T. Koppal, R. Subramaniam, and S. Yatin, Vitamin E as an antioxidant/free radical scavenger against amyloid β-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease, Rev. Neurosci. 10(2), 141-149 (1999).
82. S. M. Yatin, S., Varadaryjan, and D. A. Butterfield, Vitamin E prevents Alzheimer's amyloid β-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production, J. Alzheimers Dis. 2(2), 123-131 (2000).
83. Y. Li, L. Liu, S. W. Barger, R. E. Mrak, and W. S. Griffin, Vitamin E suppression of microglial activation is neuroprotective, J. Neurosci. Res. 66(2), 163-170 (2001).
84. C. Behl, and B. Moosmann, Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds, Biol. Chem. 383(3-4), 521-536 (2002).
85. M. Grundman, Vitamin E and Alzheimer disease: the basis for additional clinical trials, Am. J. Clin. Nutr. 71(2), 630S-636S (2000).
86. D. Offen, I. Ziv, H. Stemin, E. Melamed, and A. Hochman, Prevention of dopamine-induced cell death by thiol antioxidant: possible implications for treatment of Parkinson's disease, Exp. Neurol. 141(1), 32-39 (1996).
87. A. Roth, W. Schaffner, and C. Hertel, Phytoestrogen kaempferol (3,4′,5,7-tetrahydroxyflavone) protects PC12 and T47D cells from β-amyloid-induced toxicity, J. Neurosci. Res. 57(3), 399-404 (1999).
88. M. S. Kobayashi, D. Han, and L. Packer, Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity, Free Radic. Res. 32(2), 115-124 (2000).
89. L. Iacovitti, N. D. Stull, and A. Mishizen, Neurotransmitters, KCl and antioxidants rescue striatal neurons from apoptotic cell death in culture, Brain Res. 816(2), 276-285 (1999).
90. E. J. Lien, S. Ren, H.-H. Bui, and R. Wang, Quantitative structure-activity relationship analysis of phenolic antioxidants, Free Radic. Biol. Med. 26(3/4), 285-294 (1999).
91. H. Padh, Vitamin C: Newer insights into its biochemical functions, Nutr. Rev. 49(3), 65-70 (1991).
92. B. H. J. Bielski, and H. W. Richter, Some properties of the ascorbate free radical. Ann. N.Y. Acad. Sci. 258, 231-237 (1975).
93. R. L. Levine, Oxidative modification of glutamine synthetase: characterization of the ascorbate model system, J. Biol. Chem. 258(19), 11828-11833 (1983).
94. D. W. Choi, Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage, Trends Neurosci. 11(10), 465-469 (1988).
95. D. W. Choi, Glutamate neurotoxicity and diseases of the nervous system, Neuron 1(8), 623-634(1988).
96. P. B. McCay, Vitamin E: Interactions with free radicals and ascorbate, Ann. Rev. Nutr. 5, 323-340 (1985).
97. E. Niki, Antioxidants in relation to lipid peroxidation, Chem. Phys. Lipids 44(2-4), 227-253 (1987).
98. E. Niki, Interaction of ascorbate and α-tocopherol, Ann. N.Y. Acad. Sci. 498, 186-199 (1987).
99. J. E. Packer, T. F. Slater, and R. L. Willson, Direct observation of a free radical interaction between vitamin E and vitamin C, Nature, Lond. 278(5706), 737-738 (1979).
100. M. Scarpa, A. Rigo, M. Maiorino, F. Ursini, and C. Gregolin, Formation of α-tocopherol radical and recycling of α-tocopherol by ascorbate during peroxidation of phosphatidylcholine liposomes. An electron paramagnetic resonance study, Biochim. Biophys. Acta 801(2), 215-219 (1984).
101. F. Hruba, V. Novakova, and E. Ginter, The effect of chronic marginal vitamin C deficiency on the α-tocopherol content of the organs and plasma of guinea pigs, Experientia 38(12),1454-1455 (1982).
102. A. Bendich, L. J. Machlin, O. Scandurra, G. W. Burton, and D. N. Wayner, The antioxidant role of vitamin C, Adv. Free Radic. Biol. Med. 2, 419-444 (1986).
103. J. Huang, D. B. Agus, C. J. Winfree, S. Kiss, W. J. Mack, R. A. McTaggart, T. F. Choudhri, L. J. Kim, J. Mocco, D. J. Pinsky, W. D. Fox, R. J. Israel, T. A. Boyd, D. W. Golde, and E. S. Connolly Jr., Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke, Proc. Natl. Acad. Sci. U. S. A. 98(20), 11720-11724 (2001).
104. F. Fornai, S. Piaggi, M. Gesi, M. Saviozzi, P. Lenzi, A. Paparelli, and A. F. Casini, Subcellular localization of a glutathione-dependent dehydroascorbate reductase within specific rat brain regions, Neuroscience 104(1), 15-31 (2001).
105. M. Maden, Heads or tails? Retinoic acid will decide, Bioessays 21(10), 809-812 (1999).
106. G. Begernann, and A. Meyer, Hindbrain patterning revisited: timing and effects of retinoic acid signalling, Bioessays 23(11), 981-986 (2001).
107. G. Wolf, Vitamin A functions in the regulation of the dopaminergic system in the brain and pituitary gland, Nutr. Rev. 56(12), 354-355 (1998).
108. B. Ahlemeyer, R. Huhne, and J. Krieglstein, Retinoic acid potentiated the protective effect of NGF against staurosporine-induced apoptosis in cultured chick neurons by increasing the trk A protein expression, J. Neurosci. Res. 60(6), 767-778 (2000).
109. S. T. Omaye, Safety of megavitamin therapy, Adv. Exp. Med. Biol. 177, 169-203 (1984).
110. M. R. McCall, and B. Frei, Can antioxidant vitamins materially reduce damage in humans? Free Radic. Biol. Med. 26(7/8), 1034-1053 (1999).
111. R. E. Beyer, The participation of CoQ10 in free radical production and antioxidation, Free Radic. Biol. Med. 8(6), 545-565 (1990).
112. F. L. Crane, Development of concepts for the role of ubiquinones in biological membranes, in: Highlights in Ubiquinone Research, edited by G. Lenaz, O. Barnabei, A. Rabbi, M. Battino (Taylor & Francis, London, 1990) pp. 3-17.
113. T. Takahashi, T. Okamoto, K. Mori, H. Sayo, and T. Kishi, Distribution of ubiquinone and ubiquinol homologues in rat tissues and subcellular fractions, Lipids 28(9), 803-809 (1993).
114. L. Ernster, P. Forsmark, and K. Nordenbrand, The mode of action of lipid-soluble antioxidants in biological membranes: Relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles, BioFactors 3(4), 241-248 (1992).
115. F. Aberg, E. L. Appelkvist, G. Dallner, and L. Ernster, Distribution and redox state of ubiquinones in rat and human tissues, Arch. Biochem. Biophys. 295(2), 230-234 (1992).
116. M. E. Götz, A. Dirr, W. Gsell, R. Burger, B. Janetzky, A. Freyberger, H. Reichmann, W.-D. Rausch, and P. Riederer, Influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, lipoic acid, and L-deprenyl on the interplay between cellular redox systems, J. Neural Transm. 43 (Suppl.), 145-162 (1994).
117. C. W. Shults, R.H. Haas, D. Passov, and F. Beal, Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects, Ann. Neurol. 42(2), 261-264 (1997).
118. J. P. Sheehan, R.H. Swerdlow, W.D. Parker, S.W. Miller, R.E. Davis, and J. B. Tuttle, Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease, J. Neurochem. 68(3), 1221-1233 (1997).
119. M. E. Götz, A. Dirr, R. Burger, B. Janetzky, M. Weinmüller, W. W. Chan, S. C. Chen, H. Reichmann, W.-D. Rausch, and P. Riederer, Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 266(3), 291-300 (1994).
120. M. F. Beal, D. R. Henshaw, B. G. Jenkins, B. R. Rosen, and J. B. Schulz, Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate, Ann. Neurol. 36(6), 882-888 (1994).
121. J. B. Schulz, D. R. Henshaw, R. T. Matthews, and M. F. Beal, Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity, Exp. Neurol. 132(2), 279-283 (1995).
122. R. T. Matthews, L. Yang, S. Browne, M. Baik, and M. F. Beal, Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects, Proc. Natl. Acad. Sci. U.S.A. 95(15), 8892-8897 (1998).
123. + produces progressive neuronal degeneration which is mediated by oxidative stress, Exp. Neurol. 144(1), 193-198 (1997).
124. S. E. Stephans, T. S. Whittingham, A. J. Douglas, W. D. Lust, and B. K. Yamamoto, Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum, J. Neuochem. 71(2), 613-621 (1998).
125. M. F. Beal, Coenzyme Q10 as a possible treatment for neurodegenerative diseases, Free Radic. Res. 36(4), 455-60 (2002).
126. R. J. Ferrante, O. A. Andreassen, A. Dedeoglu, K. L. Ferrante, B. G. Jenkins, S. M. Hersch, and M. F. Beal, Therapeutic effects of coenzyme Q10 and remacide in transgenic mouse models of Huntington's disease, J. Neurosci. 22(5), 1592-1599 (2002).
127. R. P. Ostrowski, Effect of coenzyme Q(10) on biochemical and morphological changes in experimental ischemia in the rat brain, Brain Res. Bull. 53(4), 399-407 (2000).
128. H. Li, G. Klein, P. Sun, and A. M. Buchan, CoQ10 fails to protect brain against focal and global ischemia in rats, Brain Res. 877(1), 7-11 (2000).
129. M. E. Götz, A. Gerstner, R. Harth, A. Dirr, B. Janetzky, W. Kuhn, P. Riederer, and M. Gerlach, Altered redox state of platelet coenzyme Q10 in Parkinson's disease, J. Neural Transm. 107, 41-48 (2000).
130. E. Strijks, H. P. Kremer, and M. W. Horstink, Q10 therapy in patients with idiopathic Parkinson's disease, Mol. Aspects Med. 18(Suppl), S 237-240 (1997).
131. K. Lonnrot, T. Metsa-Ketela, G. Molnar, J. P. Ahonen, M. Latvala, J. Peltola, T. Pietila, and H. Alho, The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity, Free Radic. Biol. Med. 21(2), 211-217 (1996).
132. L. Packer, H. J. Tritschler, and K. Wessel, Neuroprotection by the metabolic antioxidant α-lipoic acid, Free Radic. Biol. Med. 22(1-2), 359-378 (1997).
133. A. Bast, and G. R. M. M. Haenen, Interplay between lipoic acid and glutathione in the protection against microsomal lipid peroxidation, Biochem. Biophys. Acta 963(3), 558-561 (1988).
134. H. Scholich, M. E. Murphy, and H. Sies, Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on α-tocopherol, Biochem. Biophys. Acta 1001(3), 256-261 (1989).
135. M. Panigrahi, Y. Sadguna, B. R. Shivakumar, S. V. Kolluri, S. Roy, L. Packer, and V. Ravindranath, α-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats, Brain Res. 717(1-2), 184-188 (1996).
136. P. Wolz, and J. Krieglstein, Neuroprotective effects of α-lipoic acid and its enantiomers demonstrated in rodent models of focal cerebral ischemia. Neuropharmacology 35(3), 369-375 (1996).
137. N. Aguirre, M. Barrionuevo, M. J. Ramirez, J. Del Rio, and B. Lasheras, α-Lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity, Neuroreport 10(17), 3675-3680 (1999).
138. O. A. Andreassen, R. J. Ferrante, A. Dedeoglu, and M. F. Beal, Lipoic acid improves survival in transgenic mouse models of Huntington's disease, Neuroreport 12(15), 3371-3373 (2001).
139. O. A. Andreassen, A. Dedeoglu, A. Friedlich, K. L. Ferrante, D. Hughes, C. Szabo, and M.F. Beal, Effects of an inhibitor of poly(ADP-ribose)polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice, Exp. Neurol. 168(2), 419-424 (2001).
140. M. F. McCarty, Versatile cytoprotective activity of lipoic acid may reflect its ability to activate signalling intermediates that trigger the heat-shock and phase II responses, Med. Hypotheses 57(3), 313-317 (2001).
141. L. Zhang, G. Q. Xing, J. L. Barker, Y. Chang, D. Maric, W. Ma, B. S. Li, and Rubinow, α-Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway, Neurosci. Lett. 312(3), 125-128 (2001).
142. B. Drukarch, and F. L. van Muiswinkel, Neuroprotection for Parkinson's disease: a new approach for a new millennium, Expert Opinion on Investigational Drugs 10(10), 1855-1868 (2001).
143. J. Flier, F. L. Van Muiswinkel, C. A. Jongenelen, and B. Drukarch, The neuroprotective antioxidant α-lipoic acid induces detoxication enzymes in cultured astroglial cells, Free Radic. Res. 36(6), 695-699 (2002).
144. K. Hager, A. Marahrens, M. Kenklies, P. Riederer, and G. Münch, α-Lipoic acid as a new treatment option for Alzheimer type dementia, Arch. Gerontol. Geriatr. 32(3), 275-282 (2001).
145. J. C. Watkins, P. Krogsgaard-Larsen, and T. Honore', Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists, in: Trends in Pharmacological Sciences, The Pharmacology of Excitatory Amino Acids, Special Report, edited by D. Lodge, and G. L. Collingridge, (Elsevier, Amsterdam, 1991). pp. 4-12.
146. D.T. Monaghan, R. J. Bridges, and C. W. Cotman, The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system, Ann. Rev. Pharmacol. Toxicol. 29, 365-402 (1989).
147. M. DiFiglia, M. Excitotoxic injury of the neostriatum: a model for Huntington's disease, Trends Neurosci. 13(7), 286-289 (1990).
148. M. H. M. Bakker, and A. C. Foster, An investigation of the mechanism of delayed neurodegeneration caused by direct injection of quinolinate into the rat striatum in vivo. Neuroscience 42(2), 387-395 (1991).
149. H. S. Chen, J. W. Pellegrini, S. K. Aggarwal, S. Z. Lei, S. Warach, F. E. Jensen, and S. A. Lipton, Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12(11), 4427-4436 (1992).
150. H. S. Lustig, K. V. Ahern and D. A. Greenberg, Antiparkinsonian drugs and in vitro excitotoxicity, Brain Res. 597(1), 148-150(1992).
151. D. L. Small, and A. M. Buchan, NMDA antagonists: their role in neuroprotection, Int. Rev. Neurobiol. 40, 137-171 (1997).
152. W. Danielczyk, Therapy of akinetic crises, Med. Welt 24, 1278-1282 (1973).
153. R. J. Uitti, A. H. Rajput, J. E. Ahlskog, K. P. Offord, D. R. Schroeder, M. M. Ho, M. Prasad, A. Rajput, and P. Basran, Amantadine treatment is an independent predictor of improved survival in Parkinson's disease, Neurology 46(6), 1551-1556 (1996).
154. R. J. Uitti, More recent lessons from amantadine, Neurology 52(3), 676 (1999).
155. K. L. R. Jansen, R. L. M. Faull, M. Dragunow, and B. L. Synek, Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensine, adenosine, benzodiazepine, serotonin and opioid receptors, an autoradiographic study. Neuroscience 39(3), 613-627 (1990).
156. J. W. Newcomer, and J. H. Krystal, NMDA receptor regulation of memory and behavior in humans, Hippocampus 11(5), 529-542 (2001).
157. K. A. Haberny, M. G. Paule, A. C. Scallet, F. D. Sistare, D. S. Lester, J. P. Hanig, and W. Slikker Jr., Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity, Toxicol. Sci. 68(1), 9-17 (2002).
158. B. K. Siesjö, H. Memezawa, and M. L. Smith, Neurotoxicity: pharmacological implications, Fundam. Clin. Pharmacol. 5(9), 755-767 (1991).
159. G. G. C. Hwa, and M. Avoli, The involvement of excitatory amino acids in neocortical epileptogenesis: NMDA and non-NMDA receptors. Exp. Brain Res. 86(2), 248-256 (1991).
160. B. K. Kohl, and G. Dannhardt, The NMDA receptor complex: a promising target for novel antiepileptic strategies, Curr. Med. Chem. 8(11), 1275-1289 (2001).
161. K. Williams, Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action, Curr. Drug Targets 2(3), 285-298 (2001).
162. J. Ruel, M. J. Guitton, and J. L. Puell, Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist, CNS Drug Rev. 8(3), 235-254 (2002).
163. D. M. Turetsky, L. M. T. Canzoniero, and D. W. Choi, Kainate-induced toxicity in cultured neocortical neurons is reduced by the AMPA receptor selective antagonist SYM2206, Soc. Neurosci. Abstr. 24, 578(1998).
164. J. Cartmell, and D. D. Schoepp, Regulation of neurotransmitter release by metabotropic glutamate receptors, J. Neurochem. 75(3), 889-907 (2000).
165. A. Stefani, A. Pisani, N. B. Mercuri, and P. Calabresi, The modulation of calcium currents by the activation of mGluRs, functional implications, Mol. Neurobiol. 13(1), 81-95 (1996).
166. V. Bruno, G. Battaglia, I. Ksiazek, H. van der Putten, M. V. Catania, R. Giuffrida, S. Lukic, T. Leonhardt, W. Inderbitzin, F. Gasparini, R. Kuhn, D. R. Hampson, F. Nicoletti, and P. J. Flor, Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci. 20(17), 6413-6420 (2000).
167. J. R. Brorson, P. A. Manzolillo, and R. J. Miller, Calcium entry via AMPA/KA receptors and excitotoxicity in cultured cerebellar Purkinje cells, J. Neurosci. 14(1), 187-197 (1994).
168. K. S. Lee, S. Frank, P. Vanderklish, A. Arai, and G. Lynch, Inhibition of proteolysis protects hippocampal neurons from ischemia, Proc. Natl. Acad. Sci. U. S. A. 88(16), 7233-7237 (1991).
169. C. G. Markgraf, N. L. Velajo, M. P. Johnson, D. R. McCarty, S. Medhi, J. R. Koehl, P. A. Chmielewski, and M. D. Linnik, Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 29(1), 152-158 (1998).
170. M. Miyamoto, and J. T. Coyle, Idebenone atttenuates neuronal degeneration induced by intrastriatal injection of excitotoxins, Exp. Neurol. 108(1), 38-45 (1990).
171. H. Monyer, D. M. Hartley, and D. W. Choi, 21-Aminosteroids attenuate excitotoxic neuronal injury in cortical cell cultures, Neuron 5(2), 121-126 (1990).
172. J. S. Beckman, and W. H. Koppenol, Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271(5 Pt 1), C1424-1437 (1996).
173. L. L. Dugan, S. L. Sensi, L. M. Canzoniero, S. D. Handran, S. M. Rothman, T. S. Lin, M. P.Goldberg, and D. W. Choi, Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate, J. Neurosci. 15(10), 6377-6388 (1995).
174. A. F. Schinder, E. C. Olson, N. C. Spitzer, and M. Montal, Mitochondrial dysfunction is a primary event in glutamate neurotoxicity, J. Neurosci. 16(19), 6125-6133 (1996).
175. E. P. Wei, M. D. Ellison, H. A. Kontos, and J. T. Povlishock, O2 radicals in arachidonate-induced increased blood-brain barrier permeability to proteins, Am. J. Physiol. 251(4 Pt 2), H693-699 (1986).
176. S. J. Hewett, T. F. Uliasz, A. S. Vidwans, and J. A. Hewett, Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture, J. Pharmacol. Exp. Ther. 293(3), 417-425 (2000).
177. M. P. Mattson, Stabilizing calcium homeostasis, in: Handbook of Experimental Pharmacology, CNS Neuroprotection, edited by F. W. Marcoux, and D. W. Choi (Springer-Verlag, Berlin, New York, 2002), pp. 115-153.
178. J. W. Phillis, Neuroprotection by free radical scavengers and other antioxidants, in: Handbook of Experimental Pharmacology, CNS Neuroprotection, edited by F. W. Marcoux, and D. W. Choi (Springer-Verlag, Berlin, New York, 2002), pp. 245-280.